The Medical Letter on Drugs and Therapeutics
Glyxambi - A New Combination for Type 2 Diabetes
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved Glyxambi (Boehringer Ingelheim/Lilly), a fixed-dose combination of empagliflozin (Jardiance) and linagliptin (Tradjenta), for oral treatment of type 2 diabetes in adults. It is the first combination of a sodium-glucose co-transporter 2 (SGLT2) inhibitor and a dipeptidyl peptidase-4 (DPP-4) inhibitor to be approved in the US.

STANDARD TREATMENT — Used alone, oral antihyperglycemic drugs generally lower glycated hemoglobin (HbA1c) by 0.5%-1.5%. In the absence of contraindications, metformin is the preferred first-line agent.1 If metformin does not achieve the desired goal, a second drug is usually added. If maximum doses of 2 drugs prove insufficient, a third can be added. Most patients with type 2 diabetes eventually require multi-drug therapy or insulin to achieve glycemic control. Some diabetes experts favor early use of insulin ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Glyxambi - A New Combination for Type 2 Diabetes
Article code: 1467d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian